First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

This trial is testing a combination of three drugs — sintilimab (an immunotherapy), anlotinib (a targeted anti-cancer drug), and standard platinum-based chemotherapy — as first-line treatment for malignant pleural mesothelioma, a rare and aggressive cancer of the lung lining. **You may be eligible if...** - You are 18 or older with confirmed mesothelioma that is unresectable (cannot be removed with surgery) or has spread - You have not received prior systemic treatment for advanced disease - You are in good health (ECOG 0–1) with adequate organ function - If you have stable brain metastases after local treatment, you may still be eligible **You may NOT be eligible if...** - You have received prior immunotherapy (anti-PD-1, anti-PD-L1, anti-CTLA-4 drugs) - You have active autoimmune disease requiring systemic treatment - You have significant heart conditions or uncontrolled high blood pressure - You have uncontrolled fluid around the lungs that requires frequent draining - You are pregnant or breastfeeding - You have active hepatitis B, hepatitis C, or HIV Talk to your doctor to see if this trial is right for you.